Physician profile
Robert Muller
NPI 1538377668
$5,746.64
in general payments reported to CMS, 2019-2025
33 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $88.37 · 2021: $18.31 · 2022: $577 · 2023: $1,166 · 2024: $1,266 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,928 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.30 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $775.94 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $648.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $564.62 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $552.68 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $506.20 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $394.76 | 2019-2025 | Repatha, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.58 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $250.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $245.96 | 2019-2024 | |
| Dexcom, INC. | $146.39 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $144.29 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $135.94 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Abbott Laboratories | $120.45 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $104.34 | 2019 | |
| Phathom Pharmaceuticals, INC. | $101.27 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $87.99 | 2019-2024 | Eliquis |
| Astellas Pharma US INC | $75.28 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $63.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.88 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $54.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $49.13 | 2022-2023 | Livalo, Seglentis |
| Cequr Corporation | $41.55 | 2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $40.57 | 2023-2024 | Keveyis |
| Alexion Pharmaceuticals, INC. | $34.97 | 2025 | Ultomiris |
| Medtronic, INC. | $29.42 | 2023-2025 | Minimed 780g |
| Kyowa Kirin, INC. | $27.36 | 2024 | Crysvita |
| Indivior INC. | $24.67 | 2025 | Sublocade |
| Viatris Specialty LLC | $24.00 | 2025 | Yupelri |
| Daiichi Sankyo INC. | $18.38 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.99 | 2023 | Givlaari |
| Grifols USA, LLC | $17.09 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.